Table 1

Relationship between β1 integrin expression with clinicopathologic features and classical immunohistochemical markers in breast cancer, including VEGF
Clinicopathologic Features and Immunohistochemical Markers β1 Integrin- β1 Integrin+ P-value
n (151) (%) n (74) (%)
Age (years) <50 65 43.0 27 36.5 0.213a
>50 86 67.0 47 63.5
Menstrual Status Pre-menopausal 54 35.8 24 32.4 0.367a
Post-menopausal 97 64.2 50 67.6
Size (mm) <20 49 32.5 19 25.7 0.442b
20-50 55 36.4 33 44.6
>50 47 31.1 22 29.7
Tumoral Grade I 57 37.7 25 33.8 0.845b
II 71 47.0 37 50.0
III 23 15.2 12 16.2
Lymph node Status Negative 75 49.7 33 44.6 0.283a
Positive 76 50.3 41 55.4
Clinical Stage I 22 14.6 10 13.5 0.677b
II 72 47.7 30 40.5
III 49 32.5 30 40.5
IV 8 5.3 4 5.4
Death No 116 76.8 40 54.1 0.001a
Yes 35 23.2 34 45.9
Metastasis No 115 76.2 48 64.9 0.05a
Yes 36 23.8 26 35.1
ER Negative 48 31.8 21 28.4 0.359a
Positive 103 68.2 53 71.6
PR Negative 64 42.4 33 44.6 0.431a
Positive 87 57.6 41 55.4
p53 Negative 114 75.5 51 68.9 0.187a
Positive 37 24.5 23 31.1
Ki-67 Negative 107 70.9 54 73.0 0.435a
Positive 44 29.1 20 27.0
HER2 Negative 126 83.4 52 70.3 0.019a
Positive 25 16.6 22 29.7
VEGF Negative 114 75.5 66 89.2 0.011a
Positive 37 24.5 8 10.8

aFisher’s exact test; bChi-square test.

dos Santos et al.

dos Santos et al. Diagnostic Pathology 2012 7:104   doi:10.1186/1746-1596-7-104

Open Data